SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Needham upgrades Rocket Pharmaceuticals to Buy after FDA alignment

Needham upgraded Rocket Pharmaceuticals (RCKT) to ‘Buy’ from… after the company aligned with the U.S. FDA on a pivotal study for its experimental genetic disease therapy.

RCKT

Rocket Pharmaceuticals was in focus Wednesday after Needham upgraded the biotech to Buy from its prior rating following alignment with the U.S. Food and Drug Administration on a pivotal study for its experimental genetic disease therapy.

Related stories